



**Fig. 1**




EI187447715US

Fig. 2



Q. 57. 4. Q. 58. 5. Q. 59. 6.


001000000000000000000000



**Fig. 3**


EI18744771US

09540465 . 033100



EI187447715US


09540166 • 022100




**Fig. 5**

EI187447715US

095106 - 022100




**Fig. 6A**




**Fig. 6B**

095046-033100




**Fig. 7**

EI187447715US



**Fig. 8A**



**Fig. 8B**

09540466-0332100

EI187447715US

**Fig. 9**

Response Type	Percentage of CAMs							
	BSA (500 ng)	TGF- $\beta$ 1 (20 ng)	bFGF (500 ng)	OP-1 (100 ng)	OP-1 (1000 ng)	OP-1 (100 ng) + bFGF (100 ng)	OP-1 (100 ng) + TGF- $\beta$ 1 (5 ng)	OP-1 (100 ng) + TGF- $\beta$ 1 (20 ng)
Positive	12.5	50.0	62.5	50.0	62.5	75.0	75.0	87.5
Questionable	25.0	25.0	12.5	37.5	25.0	12.5	25.0	12.5
No	62.5	25.0	25.0	12.5	12.5	12.5	0	0

© 2004 Lippincott Williams & Wilkins

**Fig. 10**

CAM Angiogenic Response						OP-1 (100 ng)	OP-1 (100 ng)	OP-1 (100 ng)
BSA (500 ng)	TGF- $\beta$ 1 (20 ng)	bFGF (500 ng)	OP-1 (100 ng)	OP-1 (1000 ng)	+	+	+	+
Grade								
Very Intense						X	X	X
Intense			X			X		
Moderate		X		X				
Weak	X							

© 2000 Lippincott Williams & Wilkins

EI187447715US